Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CBT Acquires Global Rights to CTLA-4 Checkpoint Inhibitor in $46 Million Deal

publication date: Mar 26, 2018

CBT Pharma, a California-China spin-out from Crown Bioscience (TWSE: 6554), in-licensed global rights to a CTLA-4 checkpoint inhibitor from CrownBio in a deal worth $46 million of milestones plus unspecified royalties. In 2016, CBT was spun out of CrownBio with four oncology candidates and $5 million in startup cash and then, later in the year, completed a $9.7 million Series A round led by Orbimed Asia. According to CBT, the CTLA-4 molecule is its third checkpoint inhibitor and complements its PD-1 and PD-L1 inhibitors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital